Carbine Tungsten Ltd

0
The ASX is currently closed for trading or there is no movement for this stock
Carbine Tungsten Limited, formerly Icon Resources Ltd, is engaged in the exploration for deposits of minerals. During the fiscal year ended June 30, 2010 (fiscal 2010), the Company was focused on tin, zinc and gold. Its main focus is on the Mt Carbine Tungsten mine near Cairns in north Queensland. Icon, through its 100%-owned subsidiaries, holds granted tenements and application over areas along the northwest margin of prospective Mt Isa block in northwest Queenslan... continued
advertisement
Carbine Tungsten Ltd
Carbine Tungsten Limited, formerly Icon Resources Ltd, is engaged in the exploration for deposits of minerals. During the fiscal year ended June 30, 2010 (fiscal 2010), the Company was focused on tin, zinc and gold. Its main focus is on the Mt Carbine Tungsten mine near Cairns in north Queensland. Icon, through its 100%-owned subsidiaries, holds granted tenements and application over areas along the northwest margin of prospective Mt Isa block in northwest Queensland. Its other projects include Burketown, New Century, Fitzroy, South-East Queensland, Northern NSW, Tara project and Professor Project. These project areas cover targets with potential for sediment-hosted zinc mineralization and iron oxide copper-gold-uranium deposits. Within the Burketown tenement the primary exploration target is iron oxide copper-gold mineralizing system. The Fitzroy project covers a belt of volcanic rocks to the north of Rockhampton.

Peer Comparison

Our Peer Comparison tool shows you the current top 5 and bottom 5 performing companies in the ASX.

Latest III news

CSL Analysts Shrug Off Alzheimer?s Disappointment
MAY 10, 2013
CSL Ltd , previously the government-owned Commonwealth Serum Laboratory, collects blood from blood donation centres and separates it into its constituents. The plasma collected is used to produce protein products that act as antibodies against bacteria and viruses, assist in blood clotting, work as vaccines and antivenoms and so on. Prominent among these is albumin, immunoglobulin (Ig), intravenous immunoglobulin (IVIG) and recombinant Factor 8 (rFVIII).
8656485
ALSO MENTIONS
CSL, III
FN Arena Broker Call Headlines - 8 May 2013
MAY 08, 2013
BA-Merrill Lynch rates as Neutral (3) - Baxter's Phase III clinical trial treating Alzheimer's with Immunoglobulin has failed to meet its primary end-points. BA-Merrill Lynch does not expect this to affect core Ig demand. As it does not change the broker's forecasts or alter foreseeable Ig demand, the price/earnings multiple for is being kept at 22 times.   The broker suspects the market may take a harsher view and some volatility is expected as, whilst the current Alzheimer's trials will be scrapped, a more specific sub-group patient trial may be resurrected. The Neutral rating is retained and the price target is raised to $63.31 from $60.67. More
8655101
ALSO MENTIONS
BLD, CSL, FXJ, MQG, OZL, PPT
Samsung sets record-high profit in Q1
APR 26, 2013
Samsung says demand for the Galaxy S III smartphones and the Galaxy Note devices shored up profit.
8648827
ALSO MENTIONS
III
+ MORE III NEWS
Personal Finance: tips for trading shares
Sharemarket basics: A Numbers GameLooking for shares to back? You'll need all the help you can get. Investing in shares can be something of a numbers game, especially when the financial press is peppered with mention of ratios such as "dividend yield" and "earnings per share". Sharemarket basics: How to Sell SharesWhen you didn't buy your shares in the first place, it's difficult to know where to start when you want to offload them. Allison Tait finds out how best to sell, sell, sell! Learners guide: Investing OverseasInvestors looking to diversify their portfolio could explore the option of investing overseas - after all, the Australian sharemarket represents only a small percentage of the world's markets.
+ MORE SHARE TRADING INVESTING ARTICLES


Reuters content is the intellectual property of Thomson Reuters or its third party content providers. Any copying, republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon.

"Reuters" and the Reuters Logo are trademarks of Thomson Reuters and its affiliated companies. For additional information on other Reuters media services please visit http://about.reuters.com/media/.

 FTSE®", FT-SE®", Footsie®", ["FTSE4Good®" and "techMARK"] are trade marks jointly owned by the London Stock Exchange Plc and The Financial Times Limited and are used by FTSE International Limited ("FTSE") under licence. ["All-World®", All- Share®"; and "All-Small®"; are trade marks of FTSE.] "The FTSE [NAME OF FTSE INDEX] is calculated by FTSE. FTSE does not sponsor, endorse or promote this product and is not in any way connected to it and does not accept any liability in relation to its issue, operation and trading."